Current/ Expected Orderbook/ Pending Orders?

Rahul Batra mentioned expecting a few conversions/orders in January and February which can help surpass the Rs. 230 crore revenue figure for the full year. The company currently has clear orders from some good clients in the CRAMs (contract manufacturing) division. Agreements for these clients are expected to be finalized by December, with commercial production starting by January or February. The CRAMs business has added 3 to 4 new customers this year and plans to add another 3 to 4 in the next year. No specific numeric value of the current order book or pending orders was disclosed, but the

Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. The company discusses internal CAPEX investments, such as Rs. 8.8 crores spent in H1 FY23 mainly for capacity expansion and upgradation, without indicating external fundraising. Rahul Batra mentions no major CAPEX requirements for the next 2-3 years until turnover reaches Rs. 400-450 crores, suggesting reliance on internal accruals. The company is focusing on growth via expanding exports, CRAMs, and a new Cosmetics/Dermatology division without reference to raising external funds

Any current/future capex/capital investment/strategic investment?

Beta Drugs has invested around Rs. 4 to 5 crores in scaling up a new API production line, focusing on exports, especially regulated markets (Page 4). In April 2022, installed a large Lyophilizer increasing injectable capacity threefold; invested Rs. 1.5 crores on this and Rs. 2.5 crores on upgrading injectable facilities including HVAC system and filter validations (Page 13). Rs. 8.8 crores CAPEX incurred in H1 FY23 mainly on Lyophilizer and injectable facility upgrades (Page 13). New API production line machinery installation planned to commence by December 2022 (Page 4, 13). Land acquired fo

Future growth expectations in sales/revenue/volumes?

Beta Drugs expects to achieve around Rs. 230 crores revenue for the full year, with potential to surpass this after product conversions in January-February (Page 17). Company targets 25% to 30% growth annually over the next 3-4 years, driven primarily by oncology portfolio and export markets like LATAM, African, Asian, and CIS regions (Pages 11, 13). Exports, especially formulation exports, are major growth drivers; plans to file over 200 dossiers in 2-3 years and expand market presence in regulated and semi-regulated markets (Page 4). Cosmetic-Dermatology division aims for Rs. 30-35 crores to

Future growth expectations in earnings/operating earnings/profits/EPS?

Beta Drugs expects revenue growth of 25% to 30% over the next 3-4 years, driven primarily by oncology portfolio and export expansion into LATAM, African, Asian, and CIS markets. EBITDA margins for oncology currently exceed 30-35%, with derma/cosmetology segment target margins conservatively at 15-17%, expected to improve to oncology levels once own production commences in 2-3 years. Gross margins improved from 37% (H1 last year) to ~42% this year; material cost as percentage of sales reduced from 73% to 68%. Receivable days steady around 90-96 days, indicating stable cash cycle. Operat

Beta Drugs LtdQ2 FY23Pharmaceuticals & Biotechnology

Beta Drugs Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,849.7P/E: 45.0Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Beta Drugs expects to achieve around Rs. 230 crores revenue for the full year, with potential to surpass this after product conversions in January-February (Page 17).
Company targets 25% to 30% growth annually over the next 3-4 years, driven primarily by oncology portfolio and export markets like LATAM, African, Asian, and CIS regions (Pages 11, 13).
Exports, especially formulation exports, are major growth drivers; plans to file over 200 dossiers in 2-3 years and expand market presence in regulated and semi-regulated markets (Page 4).
Cosmetic-Dermatology division aims for Rs. 30-35 crores topline in 3 years, with plans to build a strong brand and own manufacturing plant in 2-3 years (Pages 5, 16).
CRAMs (contract manufacturing) business is steadily growing with 28-30 customers and addition of new clients expected, contributing progressively to revenues (Pages 16, 17).

Margin guidance

Category 3

Beta Drugs expects revenue growth of 25% to 30% over the next 3-4 years, driven primarily by oncology portfolio and export expansion into LATAM, African, Asian, and CIS markets.
EBITDA margins for oncology currently exceed 30-35%, with derma/cosmetology segment target margins conservatively at 15-17%, expected to improve to oncology levels once own production commences in 2-3 years.
Gross margins improved from 37% (H1 last year) to ~42% this year; material cost as percentage of sales reduced from 73% to 68%.
Receivable days steady around 90-96 days, indicating stable cash cycle.
Operating cash flow dipped in H1 FY23 due to CAPEX creditor payments but overall financials remain strong.
CAPEX focus on injectable facility upgrades and new API line to support margin expansion and volume growth.
Management confident in sustaining strong earnings growth and profitability aligned with revenue trajectory and margin expansion plans.

See what Beta Drugs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
The company discusses internal CAPEX investments, such as Rs. 8.8 crores spent in H1 FY23 mainly for capacity expansion and upgradation, without indicating external fundraising.
Rahul Batra mentions no major CAPEX requirements for the next 2-3 years until turnover reaches Rs. 400-450 crores, suggesting reliance on internal accruals.
The company is focusing on growth via expanding exports, CRAMs, and a new Cosmetics/Dermatology division without reference to raising external funds.
No direct references to plans for debt or equity issuance were made during the call.

Order book

Yes

Rahul Batra mentioned expecting a few conversions/orders in January and February which can help surpass the Rs. 230 crore revenue figure for the full year.
The company currently has clear orders from some good clients in the CRAMs (contract manufacturing) division.
Agreements for these clients are expected to be finalized by December, with commercial production starting by January or February.
The CRAMs business has added 3 to 4 new customers this year and plans to add another 3 to 4 in the next year.
No specific numeric value of the current order book or pending orders was disclosed, but the tone indicates a healthy pipeline with expected growth.

See what Beta Drugs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Beta Drugs has invested around Rs. 4 to 5 crores in scaling up a new API production line, focusing on exports, especially regulated markets (Page 4).
In April 2022, installed a large Lyophilizer increasing injectable capacity threefold; invested Rs. 1.5 crores on this and Rs. 2.5 crores on upgrading injectable facilities including HVAC system and filter validations (Page 13).
Rs. 8.8 crores CAPEX incurred in H1 FY23 mainly on Lyophilizer and injectable facility upgrades (Page 13).
New API production line machinery installation planned to commence by December 2022 (Page 4, 13).
Land acquired for setting up a new plant for Dermatology and Cosmetology division, with plans to build own manufacturing plant in next 2-3 years (Pages 5, 6).
No major CAPEX expected for next 2-3 years till turnover reaches Rs. 400-450 crores, leveraging existing capacities (Page 13).

Track Beta Drugs Ltd — get its next earnings analysis in your feed

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBeta Drugs Ltd

Rev 2Mar 3

See where Beta Drugs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →